PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer

post

Bergqvist P, et al. American Association for Cancer Research® (AACR) Annual Meeting, April 2025, April 2025

This poster describes preclinical data on AbCellera’s PSMA x CD3 T-cell engagers (TCEs) for the treatment of metastatic castration-resistant prostate cancer. TCEs were generated by pairing diverse CD3- and PSMA-binding antibodies and using empirical testing to assess how TCE parameters impact function.

Together, the data presented show:

  • Potent in vitro tumor-cell killing, with one molecule showing ~10x lower EC50 than benchmark
  • Sustained in vitro activity across four rounds of serial T-cell killing
  • Preclinical in vivo efficacy, with significant tumor growth inhibition in a xenograft mouse model
  • Potential for enhanced potency when combined with costimulatory PSMA x CD28 bispecifics

DOI: 10.1158/1538-7445.AM2025-6012

Download poster

Further reading:

  1. Bergqvist P, et al. J Immunother Cancer (2024) 12:1291
  2. de Puyraimond V, et al. Cancer Res (2024) 84 (6_Supplement): 6359.
  3. Mai M, et al. Cancer Res (2024) 84 (6_Supplement): 1868. 
  4. Mai M, et al. J Immunother Cancer 2023;11(Suppl 1):A1–A1731. 
  5. Mai M, et al. Cancer Res (2023) 83 (7_Supplement): 1886. 
  6. DeVorkin L, et al. Cancer Res (2022) 82 (12_Supplement): 312. 
  7. DeVorkin L, et al. J Immunother Cancer (2022)10 (Suppl 2):A1–A1603.